BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Oncogene

Volumn 27, Issue 34, 2008, Pages 4702-4711

  Li, D ^a,b   Ambrogio, L ^a,c   Shimamura, T ^a,d   Kubo, S ^e   Takahashi, M ^e   Chirieac, L R ^d   Padera, R F ^d   Shapiro, G I ^a,d   Baum, A ^f   Himmelsbach, F ^g   Rettig, W J ^f   Meyerson, M ^a,c,d   Solca, F ^f   Greulich, H ^a,c,d   Wong, K K ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DANA FARBER HARVARD CANCER CENTER   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BIBW2992; EGFR; HER2; Lung cancer; Therapeutics

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; BIBW 2992; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; PROTEIN TYROSINE KINASE; RAPAMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE MUTATION; IN VITRO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, TRANSGENIC; NIH 3T3 CELLS; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49149118719     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.109     Document Type: Article

References (37)

1. Bedano PM, Hanna NH. (2006). Salvage therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 1: 582-587.
2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139.
3. Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates PI3K activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788-3793.
4. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
5. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H et al. (2008). A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98: 80-85.
6. Fan Z, Baselga J, Masui H, Mendelsohn J. (1993). Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637-4642.
7. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e313.
8. Hurwitz E, Klapper LN, Wilchek M, Yarden Y, Sela M. (2000). Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunol Immunother 49: 226-234.
9. Hynes NE, Lane HA. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
10. Janne PA, Engelman JA, Johnson BE. (2005). Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23: 3227-3234.
11. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. (2006). Cancer statistics, 2006. CA Cancer J Clin 56: 106-130.
12. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K et al. (2006a). The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495.
13. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A et al. (2006b). Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 103: 7817-7822.
14. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. (2005). Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65: 8968-8974.
15. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005a). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
16. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG et al. (2005b). An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65: 7096-7101.
17. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A. (2006). High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 6: 295.
18. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7670.
19. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, Debiasi RM et al. (2006). Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3: e485.
20. Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T et al. (2007a). Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest 117: 346-352.
21. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K et al. (2007b). Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respondto HKI-272 and rapamycin combination therapy. Cancer Cell 12: 81-93.
22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
23. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA et al. (2007). Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 67: 2325-2330.
24. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
25. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
26. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. (2005a). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib Is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
27. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. (2005b). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
28. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J et al. (2004). Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64: 3958-3965.
29. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES et al. (2006). Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844.
30. Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu F, Wong S et al. (2007). Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. Mol Pharmacol 71: 508-518.
31. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H et al. (2005). Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646.
32. Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K et al. (2006). Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66: 6487-6491.
33. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumors. Nature 431: 525-526.
34. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425.
35. Vikis H, Sato M, James M, Wang D, Wang Y, Wang M et al. (2007). EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 67: 4665-4670.
36. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S et al. (2006). HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10: 25-38.
37. Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS et al. (2007). Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 6: 661-667.